CSF1R and neoplasm: After radiation, TAMs are more likely to be recruited into tumors, where they may influence how tumor cells respond to therapy.389 It was shown by Stafford et al.390 that the CSF-1R inhibitor PLX3397 might suppress the differentiation of myeloid monocytes into TAMs, hence enhancing the responsiveness of glioblastoma to ionizing radiation therapy and postponing recurrence.